pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hemlibra
drug · antibody
save

emicizumab

Phase 2updated 3mo ago
by Chugai Pharmaceutical Co Ltd🔗 ChEMBL
Phase 2
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Coagulation factor IX and X

all catalysts(0)

nothing on the calendar yet

Trials studying emicizumab

  • phase3A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Diseaserecruitingn=75
  • phase3A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia Arecruitingn=360
  • phase4A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxisactive not recruitingn=136
  • phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitorsactive not recruitingn=55
  • phase1Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia Arecruitingn=40
  • phase3Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participantscompletedn=85
  • phase3SAFE Study: Safety of aPCC Following Emicizumab Prophylaxisrecruitingn=5
  • phase3A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitorscompletedn=73
more trials →

News(2)

  • After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
    With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
    fiercebiotech · 9d ago
  • Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
    Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
    biospace · 28d ago
brand
Hemlibra
trade names
Hemlibra
generic
emicizumab-kxwh
MOA
Coagulation factor IX and X other
indication
Acquired Hemophilia A
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?